Should all Stage IV Non-Small Cell Lung Cancer Be Treated Palliatively?

摘要: Non-small cell lung cancer (NSCLC) remains a major public health problem worldwide and, during the last 30 years, therapeutic advances, even if tangible, have had only modest impact on overall survival. At time of diagnosis, approximately 70% patients present with either locally advanced or metastatic disease, and cure is anecdotal particularly in disease. For NSCLC, best available treatment palliative, median survival rarely exceeds 10 months, vast majority generally dying before 18–24 months from diagnosis. Chemotherapy most frequent option used for stage IV but surgery, radiotherapy supportive care may also be useful tumor management. This chapter describes standard NSCLC devoted to disease who are candidates curative therapy.